Haleon Raises Sales Guidance But Warns Of Tougher Q4
While Haleon expects 2022 sales to grow by around 8%, the UK-based consumer health giant faces a more difficult end to the year as it begins to cycle over significant price increases rolled out towards the end of 2021.
You may also be interested in...
Haleon is taking back full control of its interests in India by terminating a distribution deal for its OTC and oral care brands signed with Hindustan Unilever in 2020.
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.
Haleon has established its Centre for Human Sciences to foster collaboration between academics in human behavior and frontline healthcare professionals. The consumer health giant hopes the initiative will help solve some of the most pressing challenges facing healthcare professionals.